Monday 27 February 2012

Lantheus ties up with Double-Crane for distribution & supply of Definity in China

Lantheus Medical Imaging, Inc., a global leader in developing, manufacturing and distributing innovative diagnostic imaging agents, entered into a strategic distribution arrangement with Beijing Double-Crane Pharmaceutical Co., LTD. (Double-Crane), a leading pharmaceutical company, for Definity Vial for (Perflutren Lipid Microsphere) Injectable Suspension in the People’s Republic of China, including Hong Kong S.A.R. and Macau S.A.R.

The board of directors of both Cos. have approved a 15-year agreement for exclusive distribution and supply of Definity, an ultrasound contrast agent for use in the field of echocardiograms. This agreement expands global access to Definity in a key geographic region. Definity is currently approved in North America, Europe, and a number of other countries.

Under the terms of the agreement, both parties will collaborate on confirmatory clinical trials to commercialize Definity in China for use in cardiac disease. Double-Crane will conduct the clinical trials and Lantheus will provide regulatory support and product for the trials.

“The distribution and supply agreement with Double-Crane supports our commitment to global expansion to help improve the treatment of human disease in key international markets,” said Don Kiepert.

Double-Crane is focused on the development of products in the area of cardiovascular disease. This partnership with Lantheus is part of Double-Crane’s strategic development plan in support of China’s “National 12th Five-Year Development Programme.” This partnership will support Double-Crane in achieving its objective to enhance its product pipeline with a globally-branded drug, such as Definity.

No comments:

Post a Comment